Scientific Agenda

Friday, 14 March 2008

8:15     
Welcome and introduction
Pieter E. Postmus, MD, PhD and Giorgio V. Scagliotti, MD, PhD

Session I: Epidemiology and screening
Chairs: Pieter E. Postmus, MD, PhD and Giorgio V. Scagliotti, MD, PhD

8:30    
The changing epidemiology of lung cancer
Carolyn Dresler, MD, MPA

8:50     
How and why to quit smoking
Jacques Cornuz, MD, MPH

9:10     
Lung cancer screening in high risk populations: Where we are heading?
Ugo Pastorino, MD
                                               
9:30     
Case & panel discussion
Ugo Pastorino, MD
                                   
10:00   
Coffee break

Session II: Staging of lung cancer
Chairs: Pieter E. Postmus, MD, PhD and
Johan F. Vansteenkiste, MD, PhD

10:30   
Staging with CT and MRI scan
Johny Verschakelen, MD

10:50   
Staging with PET and PET/CT scan
Johan F. Vansteenkiste, MD, PhD

11:10   
Invasive staging
Walter Weder, MD

11:30   
Case and panel discussion
Johan F. Vansteenkiste, MD, PhD

Session III: Targeted therapies I
Chairs: Robert Pirker, MD and Giorgio V. Scagliotti, MD, PhD

12:00   
What a physician treating lung cancer needs to know about molecular biology
Speaker invited

12:20   
EGFR inhibition: An update on tyrosine kinase inhibitors
Speaker invited

12:40   
EGFR inhibition: Monoclonal antibodies
Robert Pirker, MD

13:00   
Case and panel discussion
Speaker invited

13:30   
Lunch break

Lunch Symposium: Shaping the future of advanced NSCLC treatment
Supported by Roche
Auditorium G. Agnelli
Co-chairs: Giorgio V. Scagliotti, MD, PhD and Lucio Crinò, MD

13:30
Chair's welcome and introduction
Giorgio V. Scagliotti, MD, PhD

13:35
First-line anti-VEGF therapy: building a better future for NSCLC patients
Frank Griesinger

13:50
Assessing the evidence: experiences in second-line advanced NSCLC
Luis Paz-Ares Rodriguez

14:05
Looking to the future: novel approaches to further optimise treatment strategies
Lucio Crinò, MD

14:15
Panel discussion with audience Q & A
All faculty

14:25
Chair's close
Lucio Crinò, MD

Session IV: From Barcelona to Seoul: What has changed? Part I
Chair: Rafael Rosell, MD, PhD

15:30   
Pathology and molecular biology
Speaker invited

15:50   
NSCLC: Early disease management
Rafael Rosell, MD, PhD

16:10   
NSCLC: Metastatic disease management
Speaker invited

16:30   
Case and panel discussion
Speaker invited

17:00   
Coffee break

Session V: Debate: Is bevacizumab a new standard of care in NSCLC?
Chair:Giorgio V. Scagliotti, MD, PhD

17:30   
Pro
Christian Manegold, MD

17:45   
Con
Nicholas Thatcher, MB, BChir, PhD

18:00   
Discussion

18:15   
Adjourn

 

Saturday, 15 March 2008

Session VI: Meet the professor parallel sessions

8:00     
Front line chemotherapy in NSCLC
Nicholas Thatcher, MB, BChir, PhD

8:00     
Second and third line chemotherapy in NSCLC
Lucio Crinò, MD
           
8:00     
New treatment options in SCLC
Pieter E. Postmus, MD, PhD

Session VII: Multimodality treatment in NSCLC
Chairs: Wilfred Eberhardt, MD and Enriqueta Felip, MD

9:00     
How to optimize radiotherapy delivery in locally advanced NSCLC
Speaker invited

9:20     
Combining chemotherapy and radiotherapy in locally advanced NSCLC
Wilfried Eberhardt, MD

9:40     
Consolidation chemotherapy in locally advanced NSCLC
Enriqueta Felip, MD

10:00   
Case and panel discussion
Wilfried Eberhardt, MD

10:30   
Coffee break

Session VIII: Targeted therapies II
Chairs: Silvia Novello, MD and Johan F. Vansteenkiste, MD, PhD

11:00   
Antiangiogenesis: Multiple tyrosine kinase inhibitors
Silvia Novello, MD

11:20   
Vaccines in lung cancer
Johan F. Vansteenkiste, MD, PhD

11:40   
New targets
Egbert Smit, MD, PhD

12:00   
Case and panel discussion
Silvia Novello, MD

Session IX: Keynote lecture
Chairs: Pieter E. Postmus, MD, PhD and Giorgio V. Scagliotti, MD, PhD

12:30   
Treatment options in pleural mesothelioma
Speaker invited

13:00   
Lunch break

13:00–14:00
Lunch Symposium:
Metastatic NSCLC: Is there a standard chemotherapy ?
Supported by sanofi-aventis
Auditorium G. Agnelli
Co-chairs: Giorgio V. Scagliotti, MD, PhD and Pieter E. Postmus, MD, PhD

10 years of Taxotere in lung cancer
P. Germonpré

The optimal choice in 1st line chemotherapy
F. Grossi

Perspectives in lung cancer
C. Gridelli

Session X: From Barcelona to Seoul: What has changed? Part II
Chair: Chair invited

15:00   
What’s new in diagnosis and staging
Speaker invited

15:20  
Supportive care
Speaker invited
           
15:40  
Small cell lung cancer
Pieter E. Postmus, MD, PhD

16:00  
Case and panel discussion
Speaker invited

Session XI: Debate: Is adjuvant chemotherapy a standard of care in stage I?
Chair: Pieter E. Postmus, MD, PhD

16:30   
Pro
Robert Pirker, MD

16:45   
Con
Giorgio V. Scagliotti, MD, PhD
           
17:00   
Discussion

17:15   
Closing remarks
Pieter E. Postmus, MD, PhD and Giorgio V. Scagliotti, MD, PhD




©2007 Imedex®, LLC. All rights reserved. Reproduction in whole or part is prohibited without prior written consent from Imedex and contributing faculty.